96
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Drug sensitivity profiling identifies potential therapies for myeloid neoplasm with eosinophilia driven by a novel G3BP1-PDGFRB fusion gene

, ORCID Icon, , , , , , , , , , & show all
Pages 521-525 | Received 06 Sep 2023, Accepted 20 Dec 2023, Published online: 29 Dec 2023
 

Author contributions

XG, LX, and YZ conceived and designed the analysis; LX and XG wrote the manuscript; YL, JunW, WL, and JY collected the data; JianliW, YS, WL, JY, LZ, XW, CG, and DL contributed data or analysis tools; JianliW and LX performed the analysis. All authors agree to the content of the manuscript and its interpretations.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This study was supported by grants from Beijing Nova Program (20220484120), National Key Research and Development Program of China (2023YFC2309000), and the National Natural Science Foundation of China (82070149). We thank the Core Facilities at Suzhou Geekgene Technology Company Limited.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.